Literature DB >> 8460927

In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.

L A Collins1, G J Malanoski, G M Eliopoulos, C B Wennersten, M J Ferraro, R C Moellering.   

Abstract

The in vitro activity of RP59500, a streptogramin antibiotic, against 146 clinical isolates of vancomycin-resistant gram-positive bacteria was examined. Five strains of the species Enterococcus casseliflavus and Enterococcus gallinarum, for which the MIC of vancomycin was 8 micrograms/ml, were also studied. Twenty-eight vancomycin-susceptible strains of Enterococcus faecalis and Enterococcus faecium were included for comparison. The drug was highly active against Leuconostoc spp., Lactobacillus spp., and Pediococcus spp. (MICs, < or = 2 micrograms/ml). RP59500 was more active against vancomycin-susceptible strains of E. faecium than E. faecalis (MICs for 90% of the strains [MIC90s], 1.0 versus 32 micrograms/ml). Vancomycin-resistant strains of E. faecalis were as resistant to RP59500 as vancomycin-susceptible strains (MIC90, 32 micrograms/ml), but some vancomycin-resistant E. faecium strains were relatively more resistant to the new agent (MIC90, 16; MIC range, 0.5 to 32 micrograms/ml) than were vancomycin-susceptible organisms of this species.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8460927      PMCID: PMC187713          DOI: 10.1128/AAC.37.3.598

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500.

Authors:  S D Etienne; G Montay; A Le Liboux; A Frydman; J J Garaud
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

2.  In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods.

Authors:  K E Aldridge; D D Schiro; L M Varner
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 3.  Resistance of enterococci to glycopeptides.

Authors:  P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

4.  World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus.

Authors:  P A Maple; J M Hamilton-Miller; W Brumfitt
Journal:  Lancet       Date:  1989-03-11       Impact factor: 79.321

5.  In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

6.  RP 59500: a proposed mechanism for its bactericidal activity.

Authors:  M Aumercier; S Bouhallab; M L Capmau; F Le Goffic
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

7.  Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds.

Authors:  J C Barrière; D H Bouanchaud; J M Paris; O Rolin; N V Harris; C Smith
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

8.  Comparative in-vitro activity of RP 59500.

Authors:  L Verbist; J Verhaegen
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

  8 in total
  32 in total

1.  Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.

Authors:  S O Matsumura; L Louie; M Louie; A E Simor
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.

Authors:  H W Boucher; C B Wennersten; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 3.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 4.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

5.  In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter-related staphylococcal infections.

Authors:  R Garcia; I Raad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

Review 6.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

7.  [Antibiotic resistance of enterococci in Germany].

Authors:  C Wallrauch; E Elsner; D Milatovic; J Cremer; I Braveny
Journal:  Med Klin (Munich)       Date:  1997-08-15

8.  In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.

Authors:  George P Allen; Raymond Cha; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.

Authors:  L A Collins; G M Eliopoulos; C B Wennersten; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.